Table 4 The results of subgroup analysis and interaction tests

Age

0.430

0.384

<72

330

1.46 (1.20, 1.77)

0.001

1.36 (1.15, 1.61)

0.001

≥ 72

324

1.57 (1.31, 1.88)

< 0.001

1.48 (1.25, 1.75)

< 0.001

Gender

0.040

0.033

 Male

336

1.73 (1.42, 2.10)

< 0.001

1.59 (1.34, 1.88)

< 0.001

 Female

318

1.32 (1.10, 1.57)

0.002

1.25 (1.07, 1.46)

0.006

Hypertension

0.077

0.463

 No

420

1.35 (1.13, 1.61)

0.001

1.35 (1.16, 1.57)

0.001

 Yes

234

1.71 (1.40, 2.09)

< 0.001

1.46 (1.22, 1.75)

< 0.001

Diabetes

0.148

0.135

 No

436

1.55 (1.32, 1.82)

< 0.001

1.46 (1.26, 1.69)

< 0.001

 Yes

218

1.34 (1.06, 1.69)

0.014

1.27 (1.05, 1.54)

0.016

-

CAD

0.772

0.944

 No

379

1.47 (1.20, 1.79)

0.002

1.40 (1.18, 1.66)

0.001

 Yes

275

1.49 (1.24, 1.78)

< 0.001

1.39 (1.18, 1.64)

< 0.001

CHF

0.980

0.968

 No

310

1.50 (1.25, 1.80)

< 0.001

1.40 (1.20, 1.64)

< 0.001

 Yes

344

1.47 (1.22, 1.78)

< 0.001

1.38 (1.16, 1.64)

0.002

CKD

0.421

0.824

 No

492

1.51 (1.30, 1.75)

< 0.001

1.38 (1.21, 1.58)

< 0.001

 Yes

162

1.40 (1.04, 1.88)

0.027

1.42 (1.10, 1.83)

0.006

Liver disease

0.789

0.855

 No

517

1.47 (1.27, 1.70)

< 0.001

1.39 (1.22, 1.58)

< 0.001

 Yes

83

1.53 (1.12, 2.09)

0.007

1.39 (1.06, 1.83)

0.017

Malignancy

0.392

0.454

 No

534

1.56 (1.33, 1.82)

< 0.001

1.46 (1.27, 1.67)

< 0.001

 Yes

120

1.24 (0.99, 1.56)

0.066

1.17 (0.95, 1.44)

0.144

Obesity

0.578

0.582

 No

439

1.49 (1.26, 1.76)

< 0.001

1.40 (1.21, 1.62)

< 0.001

 Yes

215

1.51 (1.22, 1.86)

0.002

1.40 (1.15, 1.69)

0.001